Prostanoid EP 1 receptor as the target of ()-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro

Acta Pharmacologica Sinica

Volumn 33, Issue 5, 2012, Pages 701-709

  Jin, Juan ^a   Chang, Yan ^a   Wei, Wei ^a   He, Yi Fu ^a   Hu, Shan Shan ^a   Wang, Di ^a   Wu, Yu Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Epigallocatechin 3 gallate; Hepatocellular carcinoma; Prostaglandin E 2; prostanoid EP 1 receptor

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 6 [3 (4 CHLORO 2 METHYLPHENYLSULFONYLAMINOMETHYL)BICYCLO[2.2.2]OCTAN 2 YL] 5 HEXENOIC ACID; EPIGALLOCATECHIN GALLATE; PROSTAGLANDIN E RECEPTOR 1; ANTINEOPLASTIC AGENT; BICYCLO COMPOUND; CATECHIN; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HEXANOIC ACID DERIVATIVE; ONO DI 004; ONO-DI-004; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PTGER1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL DESTRUCTION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; WESTERN BLOTTING; CANCER INVASION; CELL MOTION; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; IMMUNOASSAY; LIVER TUMOR; METABOLISM; PATHOLOGY; TIME;

ALPROSTADIL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BICYCLO COMPOUNDS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CATECHIN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HEP G2 CELLS; HEXANOIC ACIDS; HUMANS; IMMUNOASSAY; LIVER NEOPLASMS; NEOPLASM INVASIVENESS; RECEPTORS, PROSTAGLANDIN E, EP1 SUBTYPE; TIME FACTORS;

EID: 84860756404     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.13     Document Type: Article

References (27)

1. Breinig M, Rieker R, Eiteneuer E, Wertenbruch T, Haugg AM, Helmke BM, et al. Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer 2008; 122: 547-57. (Pubitemid 350308945)
2. Frei B, Higdon JV. Antioxidant activity of tea polyphenols in vivo: evidence from animal studies. J Nutr 2003; 133: 3275S-84S. (Pubitemid 37222256)
3. Khan N, Afaq F, Saleem M, Ahmad N, Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (f)-epigallocatechin-3-gallate. Cancer Res 2006; 66: 2500-5.
4. Fassina G, Vene R, Morini M, Minghelli S, Benelli R, Noonan DM, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res 2004; 10: 4865-73. (Pubitemid 38955541)
5. Thangapazham RL, Singh AK, Sharma A, Warren J, Gaddipati JP, Maheshwari RK. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo. Cancer Lett 2007; 245: 232-41. (Pubitemid 44959362)
6. Ju J, Hong J, Zhou JN, Pan Z, Bose M, Liao J, et al. Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (f)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res 2005; 65: 10623-31. (Pubitemid 41743758)
7. Yang CSL, Lambert JD, Hou Z, Ju J, Lu G, Hao X. Molecular targets for the cancer preventive activity of tea polyphenols. Mol Carcinog 2006; 45: 431-5. (Pubitemid 43865851)
8. Liu W, Nakamura H, Tsujimura T, Cheng J, Yamamoto T, Iwamoto Y, et al. Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shionogi mice by a cyclooxygenase-2 inhibitor. Cancer Sci 2006; 97: 768-73. (Pubitemid 43994785)
9. Kern MA, Haugg AM, Koch AF, Schilling T, Breuhahn K, Walczak H, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. Cancer Res 2006; 66: 7059-66. (Pubitemid 44197682)
10. Han C, Michalopoulos GK, Wu T. Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J Cell Physiol 2006; 207: 261-70.
11. Kawamori T, Kitamura T, Watanabe K, Uchiya N, Maruyama T, Narumiya S, et al. Prostaglandin E receptor subtype EP(1) deficiency inhibits colon cancer development. Carcinogenesis 2005; 26: 353-7. (Pubitemid 40246556)
12. Tober KL, Wilgus TA, Kusewitt DF, Thomas-Ahner JM, Maruyama T, Oberyszyn TM. Importance of the EP(1) receptor in cutaneous UVBinduced inflammation and tumor development. J Invest Dermatol 2006; 126: 205-11. (Pubitemid 43336114)
13. Liu JF, Fong YC, Chang CS, Huang CY, Chen HT, Yang WH, et al. Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer 2010; 9: 43.
14. Sanchez-Huerta V, Gutierrez-Sanchez L, Flores-Estrada J. (f)-Epigallocatechin 3-gallate (EGCG) at the ocular surface inhibits corneal neovascularization. Med Hypotheses 2011; 76: 311-3.
15. Andreas K, Haupl T, Lubke C, Ringe J, Morawietz L, Wachtel A, et al. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther 2009; 11: R15.
16. Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 2003; 38: 756-68. (Pubitemid 37052162)
17. Wendum D, Masliah J, Trugnan G, Flejou JF. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 2004; 445: 327-33. (Pubitemid 39517756)
18. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004; 3: 1031-9. (Pubitemid 39199598)
19. Bai XM, Jiang H, Ding JX, Peng T, Ma J, Wang YH, et al. Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci 2010; 86: 214-23.
20. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY, et al. Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. Life Sci 2001; 68: 1207-14. (Pubitemid 32168047)
21. Lu YP, Lou YR, Xie JG, Peng QY, Liao J, Yang CS, et al. Topical applications of caffeine or (f)-epigallocatechin gallate (EGCG) inhibit carcinogenesis and selectively increase apoptosis in UVB-induced skin tumors in mice. Proc Natl Acad Sci USA 2002; 99: 12455-60.
22. Shirakami Y, Shimizu M, Adachi S, Sakai H, Nakagawa T, Yasuda Y, et al. (f)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci 2009; 100: 1957-62.
23. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM. Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1 betainduced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002; 33: 1097-105.
24. Cusimano A, Fodera D, Lampiasi N, Azzolina A, Notarbartolo M, Giannitrapani L, et al. Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann N Y Acad Sci 2009; 1155: 300-8.
25. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, et al. Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis 2001; 22: 2001-4. (Pubitemid 34065395)
26. Nakatsugi S, Ohta T, Kawamori T, Mutoh M, Tanigawa T, Watanabe K, et al. Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary gland carcinogenesis in rats. Jpn J Cancer Res 2000; 91: 886-92.
27. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-9.